HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3- ethyl- 1- propyl- 8- (1- (3- trifluoromethylbenzyl)- 1H- pyrazol- 4- yl)- 3,7- dihydropurine- 2,6- dione

structure in first source

Also Known As:

CVT-6883; GS-6201

Networked: 7 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - 3-ethyl-1-propyl-8-(1-(3-trifluoromethylbenzyl)-1H-pyrazol-4-yl)-3,7-dihydropurine-2,6-dione: 7
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - 3-ethyl-1-propyl-8-(1-(3-trifluoromethylbenzyl)-1H-pyrazol-4-yl)-3,7-dihydropurine-2,6-dione: 7

Experts

1.	Belardinelli, Luiz: 5 articles (01/2014 - 08/2006)
2.	Zeng, Dewan: 5 articles (01/2014 - 08/2006)
3.	Zhong, Hongyan: 5 articles (01/2014 - 08/2006)
4.	Blackburn, Michael R: 2 articles (06/2012 - 08/2006)
5.	Baiyun, Ruiqi: 1 article (03/2019)
6.	Bing, Qizheng: 1 article (03/2019)
7.	Han, Bing: 1 article (03/2019)
8.	Li, Siyu: 1 article (03/2019)
9.	Liu, Biying: 1 article (03/2019)
10.	Lu, Jingjing: 1 article (03/2019)

Related Diseases

1.	Fibrosis (Cirrhosis) 03/29/2019 - "Conversely, treatment of the selective A2BAR antagonist CVT-6883 exhibited a significant reduction in levels of fibrosis mediators and efficiently decreased cytotoxicity and inflammatory in MWCNT treated mice. " 08/01/2006 - "To investigate the role of the A2BAR in vivo, ADA-deficient mice were treated with the selective A2BAR antagonist CVT-6883, and pulmonary inflammation, fibrosis, and airspace integrity were assessed. " 01/01/2014 - "Histologic analysis showed that while both GS-6201 and enalapril decreased fibrosis in the noninfarct zone, only GS-6201 reduced the heterogeneity of fibrosis at the border, which is consistent with its effect on VT reduction. " 08/01/2006 - "In addition, treatment with CVT-6883 attenuated pulmonary inflammation and fibrosis in wild-type mice subjected to bleomycin-induced lung injury. "
2.	Asthma (Bronchial Asthma) 12/01/2008 - "Nevertheless several A2b receptor antagonists are being developed for therapeutic intervention and these are either at the preclinical stage or in phase I clinical trials as is the case for CVT-6883 for asthma." 03/01/2007 - "The present study describes the effects of a selective A(2B) AR antagonist, CVT-6883 [3-ethyl-1-propyl-8-[1-(3-trifluoromethylbenzyl)-1H-pyrazol-4-yl]-3,7-dihydropurine-2,6-dione], on airway reactivity and inflammation in an allergic mouse model of asthma. "
3.	Inflammation (Inflammations) 03/01/2007 - "The present study describes the effects of a selective A(2B) AR antagonist, CVT-6883 [3-ethyl-1-propyl-8-[1-(3-trifluoromethylbenzyl)-1H-pyrazol-4-yl]-3,7-dihydropurine-2,6-dione], on airway reactivity and inflammation in an allergic mouse model of asthma. "
4.	Vascular Remodeling 06/01/2012 - "Results demonstrated that GS-6201 treatment or genetic removal of the A(2B)R attenuated vascular remodeling and hypertension in our model. " 06/01/2012 - "To accomplish this, cellular and molecular changes in vascular remodeling were monitored in mice exposed to bleomycin in conjunction with genetic removal of the A(2B)R or treatment with the A(2B)R antagonist GS-6201. "
5.	Lung Injury 08/01/2006 - "In addition, treatment with CVT-6883 attenuated pulmonary inflammation and fibrosis in wild-type mice subjected to bleomycin-induced lung injury. "

Related Drugs and Biologics

1.	Bleomycin (Blenoxane)
2.	Purinergic P1 Receptors (Adenosine Receptor)
3.	Enalapril